These findings illustrate the therapeutic benefit of targeting proteins that negatively regulate PTEN post-translation, and corroborate the need for future work to comprehensively investigate the therapeutic benefit of targeting PTEN-negative regulators in prostate cancer with inactive PTEN, and to establish their true predictive value. Here, PTEN is linked to Familial prostate cancer.